Abstract
25 A phase 2/3 study evaluating the efficacy and safety of pozelimab in patients with CD55 deficiency with hyperactivation of complement, angiopathic thrombosis, and protein-losing enteropathy (CHAPLE disease)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have